Content Analysis of US FDA Warning Letters Issued to Compounding Pharmacies Regarding Violations of Current Good Manufacturing Practices Between 2017 and 2022 Journal of Pharmaceutical Innovation Springer Nature Link Compounded "semaglutide" is not FDA approved semaglutide.com FDA unleashes warning letters to firms selling compounded GLP 1s FDA takes first step in possible reversal of ban on some peptides The Washington Post Compounding warning letters to 503A facilities between 2017 and 2021 ScienceDirect Big news in the peptide world. , The FDA has scheduled a formal hearing in July to review 7 peptides including BPC 157 and TB 500 for legal compounding. , This isnt approval. But its